Immix Biopharma is trading at $11.12, up +5.50%, as broader markets rise. - The S&P 500 is up 0.54% and the Nasdaq Composite is up 0.89%, pointing to a risk-on session. - Immix priced a $125 million stock offering at $11.00 per share on September 29, expected to close around September 30. - The offering funds NXC-201 development and other corporate needs, but does not directly explain today's rise.